PMID- 31837035
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210110
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 43
IP  - 3
DP  - 2020 Mar
TI  - A risk prediction model for heart failure hospitalization in type 2 diabetes 
      mellitus.
PG  - 275-283
LID - 10.1002/clc.23298 [doi]
AB  - BACKGROUND: Antidiabetic therapies have shown disparate effects on 
      hospitalization for heart failure (HHF) in clinical trials. This study developed 
      a prediction model for HHF in type 2 diabetes mellitus (T2DM) using real world 
      data to identify patients at high risk for HHF. HYPOTHESIS: Type 2 diabetics at 
      high risk for HHF can be identified using information generated during usual 
      clinical care. METHODS: This electronic medical record- (EMR-) based 
      retrospective cohort study included patients with T2DM free of HF receiving 
      healthcare through a single, large integrated healthcare system. The primary 
      endpoint was HHF, defined as a hospital admission with HF as the primary 
      diagnosis. Cox regression identified the strongest predictors of HHF from 80 
      candidate predictors derived from EMRs. High risk patients were defined according 
      to the 90th percentile of estimated risk. RESULTS: Among 54,452 T2DM patients 
      followed on average 6.6 years, estimated HHF rates at 1, 3, and 5 years were 
      0.3%, 1.1%, and 2.0%. The final 9-variable model included: age, coronary artery 
      disease, blood urea nitrogen, atrial fibrillation, hemoglobin A1c, blood albumin, 
      systolic blood pressure, chronic kidney disease, and smoking history (c = 0.782). 
      High risk patients identified by the model had a >5% probability of HHF within 
      5 years. CONCLUSIONS: The proposed model for HHF among T2DM demonstrated strong 
      predictive capacity and may help guide therapeutic decisions.
CI  - (c) 2019 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
FAU - Williams, Brent A
AU  - Williams BA
AUID- ORCID: 0000-0002-7721-4483
AD  - Department of Epidemiology and Health Services Research, Geisinger Health System, 
      Danville, Pennsylvania.
FAU - Geba, Daniela
AU  - Geba D
AD  - Department of Epidemiology and Health Services Research, Geisinger Health System, 
      Danville, Pennsylvania.
FAU - Cordova, Jeanine M
AU  - Cordova JM
AD  - Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut.
FAU - Shetty, Sharash S
AU  - Shetty SS
AD  - Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut.
LA  - eng
GR  - Boehringer Ingelheim/
PT  - Journal Article
DEP - 20191214
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Aged
MH  - *Clinical Decision Rules
MH  - Clinical Decision-Making
MH  - Diabetes Mellitus, Type 2/*complications/diagnosis/drug therapy
MH  - Electronic Health Records
MH  - Female
MH  - Heart Failure/diagnosis/*etiology/therapy
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Patient Admission
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
PMC - PMC7068070
OTO - NOTNLM
OT  - diabetes
OT  - heart failure
OT  - risk prediction
COIS- The authors declare no potential conflict of interests.
EDAT- 2019/12/15 06:00
MHDA- 2020/12/22 06:00
PMCR- 2019/12/14
CRDT- 2019/12/15 06:00
PHST- 2019/07/01 00:00 [received]
PHST- 2019/10/18 00:00 [revised]
PHST- 2019/11/05 00:00 [accepted]
PHST- 2019/12/15 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2019/12/15 06:00 [entrez]
PHST- 2019/12/14 00:00 [pmc-release]
AID - CLC23298 [pii]
AID - 10.1002/clc.23298 [doi]
PST - ppublish
SO  - Clin Cardiol. 2020 Mar;43(3):275-283. doi: 10.1002/clc.23298. Epub 2019 Dec 14.